Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-12-07 2:45 pm Sale | 2023-11-30 | 13G | COHERUS ONCOLOGY, INC. CHRS | JPMORGAN CHASE & CO. JPM | 124,796 0.100% | -5,538,974 (-97.80%) | Filing History |
| 2023-10-06 2:34 pm Sale | 2023-09-30 | 13G | COHERUS ONCOLOGY, INC. CHRS | BlackRock Inc. BLK | 11,645,835 10.900% | -2,433,066 (-17.28%) | Filing History |
| 2023-05-19 09:15 am Purchase | 2023-05-18 | 13G | COHERUS ONCOLOGY, INC. CHRS | Citadel Advisors LLC | 5,815,074 6.200% | 5,815,074 (New Position) | Filing History |
| 2023-02-14 2:31 pm Sale | 2022-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | Perceptive Advisors LLC | 0 0.000% | -5,407,798 (Position Closed) | Filing History |
| 2023-02-13 7:15 pm Purchase | 2023-02-14 | 13G | COHERUS ONCOLOGY, INC. CHRS | AllianceBernstein L.P. | 6,179,005 8.000% | 510,477 (+9.01%) | Filing History |
| 2023-02-09 11:15 am Purchase | 2022-12-30 | 13G | COHERUS ONCOLOGY, INC. CHRS | VANGUARD GROUP INC | 5,815,882 7.480% | 1,268,353 (+27.89%) | Filing History |
| 2023-02-03 4:00 pm Purchase | 2022-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | STATE STREET CORPORATION STT | 6,785,982 8.720% | 2,964,862 (+77.59%) | Filing History |
| 2023-01-26 08:52 am Unchanged | 2022-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | BlackRock Inc. BLK | 14,078,901 18.100% | 0 (Unchanged) | Filing History |
| 2023-01-20 09:43 am Purchase | 2022-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | BlackRock Inc. BLK | 14,078,901 18.100% | 2,160,046 (+18.12%) | Filing History |
| 2023-01-18 1:30 pm Sale | 2022-12-30 | 13G | COHERUS ONCOLOGY, INC. CHRS | JPMORGAN CHASE & CO. JPM | 5,663,770 7.200% | -691,417 (-10.88%) | Filing History |
| 2022-02-14 6:33 pm Purchase | 2021-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | Perceptive Advisors LLC | 5,407,798 7.000% | 735,962 (+15.75%) | Filing History |
| 2022-02-14 2:45 pm Purchase | 2022-02-14 | 13G | COHERUS ONCOLOGY, INC. CHRS | AllianceBernstein L.P. | 5,668,528 7.400% | 1,012,629 (+21.75%) | Filing History |
| 2022-02-09 3:43 pm Purchase | 2021-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | VANGUARD GROUP INC | 4,547,529 5.920% | 418,594 (+10.14%) | Filing History |
| 2022-02-09 12:40 pm Sale | 2021-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | STATE STREET CORPORATION STT | 3,821,120 4.980% | -797,930 (-17.27%) | Filing History |
| 2022-01-27 5:14 pm Unchanged | 2021-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | BlackRock Inc. BLK | 11,918,855 15.500% | 0 (Unchanged) | Filing History |
| 2022-01-26 09:16 am Purchase | 2021-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | BlackRock Inc. BLK | 11,918,855 15.500% | 1,390,505 (+13.21%) | Filing History |
| 2022-01-07 3:41 pm Purchase | 2021-12-31 | 13G | COHERUS ONCOLOGY, INC. CHRS | JPMORGAN CHASE & CO. JPM | 6,355,187 8.200% | 1,392,505 (+28.06%) | Filing History |